₹ 63.35
-2.64 (-4.00%)
BSE
C
Concord Drugs
₹ 63.35
BSE
Concord Drugs EPS Summary (consolidated)
The latest quarterly EPS of Concord Drugs as of Q1 Jun 2026 stands at ₹0.85. This is a 80.85% growth quarter on quarter and 608.33% growth same quarter last year. For the FY2026 the EPS of Concord Drugs stands at ₹0.95. This is a 179.41% growth compared with FY2025.
Concord Drugs EPS
EPS by Peers

S
Sun Pharmaceutical

D
Divis Laboratories

T
Torrent Pharmaceuticals

L
Laurus Labs

Z
Zydus Life Science
*Based on consolidated figures.

Pay Zero Brokerage on Delivery
Open FREE Demat Account
+91
Or Scan the QR Code to download the Dhan App

